Picture loading failed.

Anti-GPNMB therapeutic antibody (Pre-made Glembatumumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Glembatumumab vedotin (also known as CDX-011 and CR011-vcMMAE) is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-246-1mg 1mg Inquiry
GMP-Bios-ab-246-10mg 10mg Inquiry
GMP-Bios-ab-246-100mg 100mg Inquiry
GMP-Bios-ab-246-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-GPNMB therapeutic antibody (Pre-made Glembatumumab biosimilar,Whole mAb ADC)
INN Name Glembatumumab
TargetGPNMB
FormatWhole mAb ADC
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesCuraGen Corporation;Celldex Therapeutics Inc;National Cancer Institute (USA)
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBrain cancer;Breast cancer;Malignant melanoma;Osteosarcoma;Squamous cell cancer;Uveal melanoma
Development Techna